Agendia is part of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. At Agendia, we know that cancer is a genetic disease. Without understanding the genetics of a tumor, you can’t treat it. Knowing this, we developed an advanced genomics platform for tumor gene expression profiling and built microarray assay tests that can determine whether an individual patient is at high or low risk for breast or colon cancers recurrence, helping physicians more accurately tailor cancer treatments. In addition to its focus on breast and colon cancers, Agendia has several genomic tests under research and development focusing on other cancers such as lung cancer. Agendia also collaborates with pharmaceutical companies to develop personalized drugs in the area of oncology. Agendia’s mission is to finally make personalized medicine a reality and bring high caliber innovation from research bench to bedside as efficiently as possible to benefit patients now, rather than in ten years.
MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients MammaPrint is the first FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment. Unl…
The BluePrint Molecular Subtyping Profile combined with the patient's MammaPrint test result, provides a greater level of clinical information to assist in therapeutic decision-making. BluePrint is an 80-gene expression signature which classifies breast cancer into Basal-type, Luminal-type and ERBB2-type cancers. An increasing body of evidence in the medical community suggests that breast cancer patients within these molecular…
